Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Participants should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  weeks of study drug administration; these drugs may interfere with the activity of ipilimumab and nivolumab if administered at the time of the first ipilimumab dose; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >=  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted; use of anabolic steroids is permitted
No patients that have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if <  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
No ongoing condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications; no treatment with other immunosuppressive agents within  days prior to the first dose of study drug; topical, ocular, intra-articular, intranasal, inhaled steroids and adrenal replacement steroid doses >  mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.; a brief (less than  weeks) course of corticosteroids (any amount) for prophylaxis (for example: contrast dye allergy) or for treatment of non-autoimmune conditions (for example: delayed-type hypersensitivity reaction caused by a contact allergen) is permitted if >  days since last dose
Prior or current systemic immunosuppressive therapy (>  mg/day prednisone equivalents) within  days prior to CD of study therapy; inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease\r\n* Adrenal replacement doses are permitted in the absence of active autoimmune disease
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  weeks of the study drug administration. Note: Adrenal replacement doses ?  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
Other medications (meds:)\r\n* Participants who are receiving any other investigational agents\r\n* Immunosuppressive medications / steroids\r\n** Subject must not require high dose systemic corticosteroids defined as dexamethasone >  mg/day or bioequivalent for at least  consecutive days within  weeks prior to day  of study therapy\r\n** Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\r\n** Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)\r\n** Physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents\r\n** A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within  days prior to first dose of study drug (except that inhaled or topical corticosteroids or brief courses of corticosteroids given for prophylaxis of contrast dye allergic response are permitted).
Use of corticosteroids or immunosuppressive medication is exclusionary, except the following in the absence of active autoimmune disease:\r\n* Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, ocular, intra articular, intranasal, and inhaled);\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent are permitted;\r\n* Adrenal replacement steroid doses including doses >  mg daily prednisone are permitted;\r\n* A brief (less than  weeks) course of corticosteroids for prophylaxis (e.g. CT scan premedication against contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration (i.e. disease-modifying antirheumatic drugs). Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Note that subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if > mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergen) is permitted.
Current or prior use of immunosuppressive medication  days before the first dose of nivolumab or ipilimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed  mg/day of prednisone, or an equivalent corticosteroid; a brief course (=<  days) of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients who are on high dose steroid (e.g., >  mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g., infliximab). Topical, inhaled, intraarticular, ocular, or intranasal corticosteroids (with minimal systemic absorption) are allowed. A brief course (<  hours) of systemic corticosteroids for prophylaxis (e.g., from contrast dye allergy) is permitted. Physiological corticosteroid replacement therapy for adrenal insufficiency is also permitted.
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should not have any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug\r\n* NOTE: Inhaled or topical steroids and adrenal replacement steroids at any dose are permitted in the absence of active autoimmune disease; a brief (less than  weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Patients are excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients are ineligible who have any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications =<  days prior to registration\r\n* NOTE: inhaled steroids and adrenal replacement steroid doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than  weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients who are on high dose steroid (e.g., >  mg prednisone daily or equivalent) or other more potent immune suppression medications (e.g., infliximab); topical, inhaled, intra-articular, ocular, or intranasal corticosteroids (with minimal systemic absorption) are allowed; a brief course (=<  hours) of systemic corticosteroids for prophylaxis (e.g., from contrast dye allergy) is permitted
Current use of immunosuppressive medication, except the following:\r\n* Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, intra-articular, intranasal, and inhaled);\r\n* Systemic corticosteroids at physiologic doses =<  mg/day of prednisone or equivalent are permitted;\r\n* A brief (less than  weeks) course of corticosteroids for prophylaxis (e.g. CT scan premedication against contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should not have any condition requiring systemic treatment with corticosteroids (<  mg daily prednisone equivalents) or other immunosuppressive medications =<  days prior to registration\r\n* NOTE: Inhaled or topical steroids and adrenal replacement steroid doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than  weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses >=  mg prednisone or any other form of systemic immunosuppressive therapy within  days prior to the first dose of trial treatment; subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course (=<  days) of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Permitted therapies include topical, ocular, intra?articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (e.g. delayed?type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within  days of study drug administration; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Prior or current systemic immunosuppressive therapy (>  mg/day prednisone equivalents) within  week prior to CD of study therapy; inhaled, ocular, intra-articular, intranasal, and topical corticosteroids are permitted in absence of active autoimmune disease\r\n* Adrenal replacement doses are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other systemic immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)' physiologic replacement doses of systemic corticosteroids are permitted, even if <  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if <  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Has a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). A brief course of corticosteroids for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergens) is permitted
Patients requiring systemic treatment with corticosteroids (> mg daily prednisone equivalents) or other immunosuppressive medications =<  days prior to first dose of study drug are not eligible\r\n* NOTE: Inhaled and intranasal corticosteroids are permitted; a brief (less than  weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Patients requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Study participants who have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if <  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients are excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration, with the exception of a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen); participants are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption)
Patients are ineligible who have any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days prior to first dose of study drug; Note: inhaled steroids and adrenal replacement steroid doses >  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than  weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
Condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Current or prior use of immunosuppressive doses of systemic corticosteroids (>  mg/day prednisone equivalents) or other immunosuppressive medications within  weeks of study drug administration; NOTE: subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients are excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses <  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if <  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen\r\n* Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =<  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalents) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if >  mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen), or as pre-phase treatment for cytoreduction; patients will receive steroids with blinatumomab to reduce cytokine release syndrome (CRS) as specified in the protocol
